Movement Alert｜Merck Rises 3.02% in Regular Trading, EU Injunction Against Keytruda SC Seen Benefiting Halozyme

Market Focus

8 hours ago

On October 10, Merck rose 3.02% in regular trading, trading at $146.68 per share, with turnover of $571 million.

The move followed a Dutch patent court ruling that imposed an injunction on Merck's Keytruda SC in multiple EU markets. The court found the subcutaneous version infringed Halozyme Therapeutics' MDASE patent and rejected Merck's validity challenge. The restriction applies to Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The intravenous version of Keytruda remains unaffected. Separately, Merck announced a global license agreement for SPR 2015, a preclinical oral KRAS G12D molecular glue degrader, with a potential total value of $2.13 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1150897362"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150897362\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150897362?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-10 01:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150897362","market":"us","top_or_hot":-1,"title":"Movement Alert｜Merck Rises 3.02% in Regular Trading, EU Injunction Against Keytruda SC Seen Benefiting Halozyme","media":"Market Focus","content":"<p><p>On October 10, Merck rose 3.02% in regular trading, trading at $146.68 per share, with turnover of $571 million.</p><p>The move followed a Dutch patent court ruling that imposed an injunction on Merck's Keytruda SC in multiple EU markets. The court found the subcutaneous version infringed Halozyme Therapeutics' MDASE patent and rejected Merck's validity challenge. The restriction applies to Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The intravenous version of Keytruda remains unaffected. Separately, Merck announced a global license agreement for SPR 2015, a preclinical oral KRAS G12D molecular glue degrader, with a potential total value of $2.13 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Merck Rises 3.02% in Regular Trading, EU Injunction Against Keytruda SC Seen Benefiting Halozyme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Merck Rises 3.02% in Regular Trading, EU Injunction Against Keytruda SC Seen Benefiting Halozyme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-10 01:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 10, Merck rose 3.02% in regular trading, trading at $146.68 per share, with turnover of $571 million.</p><p>The move followed a Dutch patent court ruling that imposed an injunction on Merck's Keytruda SC in multiple EU markets. The court found the subcutaneous version infringed Halozyme Therapeutics' MDASE patent and rejected Merck's validity challenge. The restriction applies to Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The intravenous version of Keytruda remains unaffected. Separately, Merck announced a global license agreement for SPR 2015, a preclinical oral KRAS G12D molecular glue degrader, with a potential total value of $2.13 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"","article_id":"1150897362","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150897362","pubTimestamp":1791567682,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 10, Merck rose 3.02% in regular trading, trading at $146.68 per share, with turnover of $571 million.The move followed a Dutch patent court ruling that imposed an injunction on Merck's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"走势警报|默沙东常规交易上涨 3.02%，欧盟对 Keytruda SC 的禁令被视为有利于 Halozyme","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"On October 10, Merck rose 3.02% in regular trading, trading at $146.68 per share, with turnover of $571 million.The move followed a Dutch patent court ruling that imposed an injunction on Merck's Keytruda SC in multiple EU markets. The court found the subcutaneous version infringed Halozyme Therapeutics' MDASE patent and rejected Merck's validity challenge. The restriction applies to Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The intravenous version of Keytruda remains unaffected. Separately, Merck announced a global license agreement for SPR 2015, a preclinical oral KRAS G12D molecular glue degrader, with a potential total value of $2.13 billion.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}